BMS Harnesses Enterome’s Microbiome Technology in Immuno-Oncology
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 12 (Table of Contents)
Published: 7 Dec-2016
DOI: 10.3833/pdr.v2016.i12.2209 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an attempt to expand the scope of its immuno-oncology franchise, Bristol-Myers Squibb (BMS) is to leverage French start-up Enterome Bioscience’s metagenomics platform in a collaboration that aims to develop companion diagnostics and microbiome-related therapeutics for the treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS